COMBINATION OF NIRAPARIB AND ANLOTINIB IN PATIENTS WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER: AN OPEN-LABEL, SINGLE-ARM, TWO-STAGE, PHASE II STUDY

被引：0
|
作者：
Ren, Yulan [1 ,2 ]
Lu, Jing [2 ,3 ]
Tian, Wenjuan [1 ,2 ]
Li, Haiming [2 ,3 ]
Wang, Huaying [1 ,2 ]
机构：
[1] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Radiol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP148/#437
引用
收藏
页码：A107 / A107
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [2] An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
    Li, J.
    Wei, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S772 - S772
  • [3] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Rubinstein, Maria M.
    Hyman, David
    Caird, Imogen
    O'Cearbhaill, Roisin
    Grisham, Rachel
    Tew, William
    Hensley, Martee
    Sabbatini, Paul
    Aghajanian, Carol
    Iasonos, Alexia
    Won, Helen
    Selcuklu, Duygu
    Zimel, Catherine
    Makker, Vicky
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 50 - 50
  • [6] A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
    Atkins, Sarah L. P.
    Greer, Yoshimi Endo
    Jenkins, Sarah
    Gatti-Mays, Margaret E.
    Houston, Nicole
    Lee, Sunmin
    Lee, Min-Jung
    Rastogi, Shraddha
    Sato, Nahoko
    Burks, Christina
    Annunziata, Christina M.
    Lee, Jung-Min
    Nagashima, Kunio
    Trepel, Jane B.
    Lipkowitz, Stanley
    Zimmer, Alexandra S.
    ONCOLOGIST, 2023, 28 (10): : E919 - E972
  • [7] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [9] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Huang, Q.
    Liu, G.
    Tu, H.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Zheng, M.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S734 - S734
  • [10] Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.
    Wang, Xipeng
    Li, Jiarui
    Zhang, Ping
    Fang, Xuhong
    Wang, Yizhi
    Sun, Huizhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17545 - E17545
12345